The goal of this study is to test whether monitoring insulin levels and using pioglitazone to treat hyperglycemia and hyperinsulinemia in patients treated with Alpelisib for metastatic breast cancer is feasible and safe, and to assess the rates of glycemic control, dose reductions and treatment discontinuation and the progression free survival of patients treated with this regimen.
Patients with ER positive HER2 negative metastatic breast cancer, harboring an activating PIK3CA mutation, scheduled to start treatment with Alpelisib and fulvestrant.
Ages 18 - 85
ECOG performance status 0, 1 or 2
Ability to understand and willingness to sign a written informed consent.
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of Alpelisib
Uncontrolled diabetes mellitus, defined as HbA1c above 8%
Diabetes mellitus controlled by insulin
Uncontrolled intercurrent illness including, but not limited to: active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Single group
Pioglitazone
Drughyperinsulinemia and hyperglycemia
Rate of severe (grade 3 and 4) hyperglycemia in patients enrolled in the study and in patients treated per protocol
Rate of all grade hyperglycemia in patients enrolled in the study and in patients treated per protocol
Progression free survival in patients enrolled in the study and in patients treated per protocol
Click on the lead sponsor to view all of their trials.
